Zhongping Capital
中平资本
Zhongping Capital (中平资本) is a Chinese investment fund that has led two major funding rounds in elsewhere's coverage: a B4 round of over RMB 400 million in Bluepha (蓝晶微生物) in early 2023, and a nearly RMB 500 million round in CasCade Therapeutics (凯思凯迪) in February 2026 . Both deals were in the biotech space — synthetic biology and innovative drug R&D targeting nuclear receptors and GPCRs, respectively — suggesting a focus on life sciences. The fund co-invested alongside state-backed entities such as Jiangsu Huanghai Financial Holding Group and Guoshou Capital in these rounds . elsewhere's corpus does not contain additional detail on the fund's founding, team, or broader portfolio.
AI-generated — may contain errors, please verify.
Coverage
Rongbao | Karl Dynamics, Aerofugia, StarsComm, and ImmuPeak Kick Off the Year with Major Funding Rounds
Leading the industry into a new era.
CasCade Therapeutics Closes Nearly 500 Million Yuan Major Funding Round, Targeting Nuclear Receptor and GPCR Innovative Drug R&D
Dedicated to becoming a global leader in metabolic disease therapeutics.
Setting Off in Spring: 7 Early-Stage Companies Raise Over 800 Million | FreeS Family Funding News · Vol 14
Looking forward to working with more outstanding founders.
